Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Trial of CTT1403 in mCRPC
NCT03822871Phase 1Completed
- Sponsor
- Cancer Targeted Technology
- Start
- Apr 2019
- Primary completion
- Oct 2022
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label trial of CTT1403 in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Cancer Targeted Technology. Primary endpoints: Frequency of Dose-limiting Toxicity and Objective Response Rate. Started Apr 2019; status: completed.
02
Drugs
CTT1403
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03822871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03822871.